Overview

Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects

Status:
COMPLETED
Trial end date:
2024-02-05
Target enrollment:
Participant gender:
Summary
This clinical study is a single-center, randomized, double-blind, placebo-controlled Phase 1 clinical study to assess the PK characteristics and safety and tolerability of single and multiple dose daridorexant in 32 healthy adult Chinese subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Jiangsu Simcere Pharmaceutical Co., Ltd.
Treatments:
daridorexant